Cadrenal Therapeutics retains Tungsten Advisors for strategic review
Cadrenal Therapeutics said it retained Tungsten Advisors to lead a formal strategic process to maximize value of its orphan thrombo-inflammatory therapeutics.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.